Cabot Corporation 10-Q Summary: Quarter Ended March 31, 2004
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for Cabot Corporation, a specialty chemicals and materials company, for the period ended March 31, 2004. The company operates through three primary segments: Chemical Business, Cabot Supermetals, and Specialty Fluids. The report covers the second quarter of fiscal year 2004 and the first six months of the fiscal year.
Key Financial Metrics
| Metric | Q2 2004 (3 Months) | Q2 2003 (3 Months) | YTD 2004 (6 Months) | YTD 2003 (6 Months) |
|---|---|---|---|---|
| Net Sales ($ millions) | $500 | $466 | $946 | $876 |
| Gross Profit ($ millions) | $131 | $127 | $238 | $244 |
| Gross Margin (%) | 26% | 27% | 25% | 28% |
| Net Income ($ millions) | $37 | $23 | $66 | $57 |
| Diluted EPS ($) | $0.54 | $0.33 | $0.96 | $0.81 |
| Cash from Operations ($ millions) | N/A | N/A | $93 | $59 |
| Cash and Equivalents ($ millions) | $257 | N/A | $257 | N/A |
| Total Debt ($ millions) | $574 | N/A | $574 | N/A |
Note: Total Debt is the sum of Notes payable to banks ($30M), Current portion of long-term debt ($25M), and Long-term debt ($519M) as of March 31, 2004.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 7% in Q2 and 8% YTD compared to the prior year, driven by volume increases in the Chemical and Specialty Fluids segments and favorable foreign currency translation.
- Profitability: Net income rose 61% in Q2 ($37M vs. $23M) and 16% YTD ($66M vs. $57M). This improvement is largely attributable to the absence of a $22 million investment impairment charge recorded in Q2 2003.
- Segment Performance:
- Chemical Business: Sales up 13% and profit up 87% (Q2) due to higher tire volumes and growth in inkjet colorants.
- Supermetals: Sales down 21% and profit down 56% (Q2) due to the expiration of intermediate product contracts.
- Specialty Fluids: Sales up significantly (from $3M to $9M in Q2) driven by Statoil project volumes.
- Costs: Selling and administrative expenses remained flat year-over-year as savings initiatives offset increases in legal fees and salaries.
Outlook, Risks, and Contingencies
- Restructuring: The company initiated a European restructuring plan in May 2003. Total estimated pre-tax charges are approximately $65 million. As of March 31, 2004, $49 million has been recorded, with an additional $7 million expected over the next 12-15 months. This includes severance, asset retirement obligations, and impairments.
- Legal Proceedings:
- Respirator Claims: A $20 million reserve exists for claims related to an acquired safety respiratory business (American Optical Corporation), involving approximately 91,000 pending claimants.
- Environmental: A $26 million reserve is held for environmental remediation costs, primarily related to divested businesses.
- Antitrust: The company is defending against antitrust suits regarding carbon black pricing and a new antitrust action filed by AVX Corporation regarding tantalum supply agreements.
- Capital Expenditures: Expected to be approximately $130 million for fiscal 2004, including a $3 million contribution to a joint venture in China.
- Dividends: Quarterly dividend increased to $0.15 per share (from $0.13 in the prior year).
Investor Verification Checklist
- Verify the sustainability of the Chemical Business volume growth, specifically in tire-related carbon black and inkjet colorants.
- Monitor the timeline and final cost of the European restructuring plan, particularly the remaining $7 million in expected charges.
- Review the status of the $20 million respirator liability reserve and the $26 million environmental reserve for potential increases.
- Assess the impact of the Supermetals segment's contract expirations on future revenue stability.
- Confirm the outcome of pending antitrust litigation, specifically the AVX Corporation case and carbon black class actions.